Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence, Healthy Volunteers
Trial Timeline
Jul 3, 2017 → Jul 17, 2017
NCT ID
NCT03213353About Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution
Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solution is a phase 1 stage product being developed by Johnson & Johnson for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT03213353. Target conditions include Bioequivalence, Healthy Volunteers.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03213353 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence